Click Therapeutics has snapped up the assets of troubled digital health company Better Therapeutics, including its FDA-approved prescription digital therapeutic (PDT) for
Digital investment in the pharma sector is continuing at a steady pace but could fall behind what is needed to deliver true transformation of their businesses.
Treatments emerging from the digital therapeutics space were once greeted with optimism, due to the potential to aid patients’ health through technology, rather than pharmaceuticals.
Otsuka and Click Therapeutics’ Rejoyn has become the first prescription digital therapeutic (DTx) to be approved by the FDA for people with major depressive disorder.
Among the many struggles faced by the digital therapeutics industry is the difficulty of designing and running effective clinical trials of digital therapeutics.
Swedish pharma company Vicore has won breakthrough status from the FDA for Almee, a cognitive behavioural therapy (CBT) app used to support people with pulmonary fibrosis